Universidade de Santiago de Compostela-ko ikertzaileekin lankidetzan egindako argitalpenak (23)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

2022

  1. A genome-wide association study of survival in patients with sepsis

    Critical Care, Vol. 26, Núm. 1

  2. CHARACTERIZING COVID-19-RELATED RETINAL VASCULAR OCCLUSIONS: A Case Series and Review of the Literature

    Retina (Philadelphia, Pa.), Vol. 42, Núm. 3, pp. 465-475

  3. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

2018

  1. Improved in vitro corneal delivery of a thrombospondin-1-derived peptide using a liposomal formulation

    Experimental Eye Research, Vol. 167, pp. 118-121

  2. Sorbitan ester nanoparticles (SENS) as a novel topical ocular drug delivery system: Design, optimization, and in vitro/ex vivo evaluation

    International Journal of Pharmaceutics, Vol. 546, Núm. 1-2, pp. 20-30

2017

  1. Designing lipid nanoparticles for topical ocular drug delivery

    International Journal of Pharmaceutics, Vol. 532, Núm. 1, pp. 204-217

2015

  1. Predicting proliferative vitreoretinopathy: Temporal and external validation of models based on genetic and clinical variables

    British Journal of Ophthalmology, Vol. 99, Núm. 1, pp. 41-48

2014

  1. Nanoparticles based on naturally-occurring biopolymers as versatile delivery platforms for delicate bioactive molecules: An application for ocular gene silencing

    International Journal of Pharmaceutics, Vol. 477, Núm. 1, pp. 12-20

2013

  1. A genetic case-control study confirms the implication of SMAD7 and TNF locus in the development of proliferative vitreoretinopathy

    Investigative Ophthalmology and Visual Science, Vol. 54, Núm. 3, pp. 1665-1678

  2. A nanomedicine to treat ocular surface inflammation: Performance on an experimental dry eye murine model

    Gene Therapy, Vol. 20, Núm. 5, pp. 467-477

2011

  1. Activation of MAPK signaling pathway and NF-κB activation in pterygium and ipsilateral pterygium-free conjunctival specimens

    Investigative Ophthalmology and Visual Science, Vol. 52, Núm. 8, pp. 5842-5852

  2. Expression of MUC5AC in ocular surface epithelial cells using cationized gelatin nanoparticles

    Molecular Pharmaceutics, Vol. 8, Núm. 5, pp. 1783-1788

  3. Intracellular trafficking of hyaluronic acid-chitosan oligomerbased nanoparticles in cultured human ocular surface cells

    Molecular Vision, Vol. 17, pp. 279-290

2010

  1. A strong genetic association between the tumor necrosis factor locus and proliferative vitreoretinopathy: The Retina 4 Project

    Ophthalmology, Vol. 117, Núm. 12

  2. Ocular tolerance to a topical formulation of hyaluronic acid and chitosan-based nanoparticles

    Cornea, Vol. 29, Núm. 5, pp. 550-558

2009

  1. Development of predictive models of proliferative vitreoretinopathy based on genetic variables: The retina 4 project

    Investigative Ophthalmology and Visual Science, Vol. 50, Núm. 5, pp. 2384-2390

2007

  1. Ocular drug delivery by liposome-chitosan nanoparticle complexes (LCS-NP)

    Biomaterials, Vol. 28, Núm. 8, pp. 1553-1564

2006

  1. Chitosan nanoparticles as a potential drug delivery system for the ocular surface: Toxicity, uptake mechanism and in vivo tolerance

    Investigative Ophthalmology and Visual Science, Vol. 47, Núm. 4, pp. 1416-1425

  2. Photodynamic therapy in subfoveal and juxtafoveal idiopathic and postinflammatory choroidal neovascularization

    Acta Ophthalmologica Scandinavica, Vol. 84, Núm. 6, pp. 743-748